Skip to main content
RZLT
NASDAQ Life Sciences

Rezolute's upLIFT Phase 3 Hits Primary Endpoint in Tumor Hyperinsulinism

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$3.91
Mkt Cap
$374.341M
52W Low
$1.07
52W High
$11.165
52W Position info
265% above low
Off High info
65% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

RZLT has more than doubled off its 52-week low of $1.07.

Summary

Rezolute's Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism met its primary efficacy endpoint on preliminary data from a November 5th evaluation. Thirteen of 16 participants hit the responder bar — at least a 50% cut in glucose infusion rate — and 12 of those fully stopped IV glucose; statistical significance required at least 9 responders. That is a clean win for a program that had been overshadowed by the sunRIZE miss in congenital HI on November 2nd, and it keeps a second BLA path alive. Full topline results, including the formal statistical analysis, are due mid-December 2026, with FDA discussions planned for Q1 2027 ahead of potential BLA submissions in both tumor and congenital HI next year. The timing matters: the company launched a Morgan Stanley-led underwritten offering this morning with cash at $90.0M and has now priced a $100M public offering of common stock and pre-funded warrants, so a positive registrational read strengthens the equity story behind that raise. Watch the mid-December topline for the confidence interval and the three participants still in the pivotal period.

At the time of this announcement, RZLT was trading at $3.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $374.3M. The 52-week trading range was $1.07 to $11.17. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

RZLT - Latest Insights

RZLT
Nov 13, 2026, 12:27 PM EST
Source: Benzinga
Importance Score:
8
Price at Filing: $3.81
Real-time Price: $3.66 info
Change: -$0.150 (-4%) info
Market Cap: $353.544M info
RZLT
Nov 13, 2026, 6:26 AM EST
Filing Type: FWP
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $3.66 info
Change: -$0.535 (-13%) info
Market Cap: $353.544M info
RZLT
Nov 13, 2026, 6:19 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $4.09
Real-time Price: $3.66 info
Change: -$0.435 (-11%) info
Market Cap: $353.544M info
RZLT
Nov 13, 2026, 6:15 AM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $3.87
Real-time Price: $3.66 info
Change: -$0.215 (-6%) info
Market Cap: $353.544M info
RZLT
Nov 05, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.64
Real-time Price: $3.66 info
Change: +$0.015 (+0.41%) info
Market Cap: $353.544M info